Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors

NCT04630522 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

295

Enrollment

INDUSTRY

Sponsor class

Conditions

Bone Metastases From Solid Tumors

Interventions

DRUG: Drug: JMT103- 120 mg SC Q4W
DRUG: Drug: JMT103- 120 mg SC Q8W
DRUG: Drug: JMT103- 180 mg SC Q8W
DIETARY_SUPPLEMENT: Dietary Supplement: Calcium Dietary Supplement: Vitamin D

Sponsor

Shanghai JMT-Bio Inc.